4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,574,607 | -29.6% | 437,911 | 0.0% | 1.23% | -17.0% |
| Q2 2023 | $7,913,052 | +5.1% | 437,911 | 0.0% | 1.48% | +1.0% |
| Q1 2023 | $7,527,690 | -22.6% | 437,911 | 0.0% | 1.46% | -34.7% |
| Q4 2022 | $9,726,003 | +228.4% | 437,911 | +18.9% | 2.24% | +230.0% |
| Q3 2022 | $2,962,000 | +62.3% | 368,411 | +40.9% | 0.68% | +60.0% |
| Q2 2022 | $1,825,000 | -8.6% | 261,423 | +97.9% | 0.42% | -13.6% |
| Q1 2022 | $1,997,000 | -31.1% | 132,090 | 0.0% | 0.49% | -30.3% |
| Q4 2021 | $2,898,000 | +88.2% | 132,090 | +131.4% | 0.71% | +44.7% |
| Q3 2021 | $1,540,000 | +12.0% | 57,090 | 0.0% | 0.49% | +3.4% |
| Q2 2021 | $1,375,000 | -36.6% | 57,090 | +14.2% | 0.47% | -44.5% |
| Q1 2021 | $2,169,000 | +4.6% | 50,000 | 0.0% | 0.85% | -35.8% |
| Q4 2020 | $2,073,000 | – | 50,000 | – | 1.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |